Skip to main content
. Author manuscript; available in PMC: 2009 Nov 1.
Published in final edited form as: J Mol Cell Cardiol. 2008 Jul 18;45(5):610–616. doi: 10.1016/j.yjmcc.2008.07.003

Figure 3. Inhibition of Cdk2 activity with Roscovitine attenuates infarct size in vivo.

Figure 3

C57/BL6 mice were subjected to 30-min coronary occlusion followed by 24h of reperfusion. Mice were injected intraperitoneally two hours prior to ischemia (Pre) or 20 minutes after coronary ligation (Post) with 2.8 µg/gm of Roscovitine or DMSO carrier. A. Representative TTC-stained hearts from vehicle or pretreated hearts after I/R injury are shown. B. Cdk2 kinase assays demonstrate reduced 32P-labeling of purified histones consistent with decreased Cdk2 activity in Roscovitine-treated hearts after I/R when compared to vehicle-treated hearts. IFS in Pre- or Post-Roscovitine-treated mice were reduced compared to control vehicle-treated mice (*P<0.001; n=6 per group).